First three months of anticoagulation for venous thromboembolism in non-cancer patients: LMWH VS. VKAs. Findings from the RIETE registry
Thrombosis Update · 2020
DOI: 10.1016/j.tru.2020.100010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thrombosis Update, 2020. Verfasst von Manuel J. Núñez Fernández und 39 weiteren Autor:innen. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Massachusetts General Hospital, Harvard Medical School.
Themen: Thromboseprophylaxe, Onkologische Pflege
Abstract (Originalsprache)
The use of low-molecular-weight heparin (LMWH) for long-term therapy of venous thromboembolism (VTE) in patients without cancer has not been consistently evaluated. We used the data in the RIETE registry to compare the 3-month outcomes (VTE recurrences, major bleeding or death) in non-cancer patients with VTE, according to long-term therapy with LMWH or vitamin K antagonists (VKAs). As of March 2018, 14,582 non-cancer patients with VTE had received initial therapy with LMWH and then switched to VKAs, while 9151 were prescribed LMWH for initial and long-term therapy. Overall, 11,494 had initially presented with pulmonary embolism (PE) and 12,239 with isolated deep vein thrombosis (DVT). Among 11,494 patients initially presenting with PE, 84 had VTE recurrences, 204 major bleeding and 406 died. Among 12,239 patients with isolated DVT, 133 developed VTE recurrences, 137 bled and 289 died. On propensity score analysis, PE patients on long-term LMWH therapy were at increased risk for PE recurrences (OR: 3.30; 95%CI: 1.67–6.48), major bleeding (OR: 1.68; 95%CI: 1.21–2.32) or death (OR: 3.16; 95%CI: 2.43–4.09) compared with those receiving VKAs. In patients with DVT, those on long-term LMWH also were at increased risk for PE recurrences (OR: 2.31; 95%CI: 1.13–4.73), major bleeding (OR 2.28; 95%CI: 1.51–3.44) or death (OR: 2.32; 95%CI: 1.54–3.51). In the RIETE non-cancer patients with VTE, long-term therapy with VKAs was associated with a lower risk for recurrences, major bleeding or death.
Förderung
- Massachusetts General Hospital
- Harvard Medical School
Zitieren
APA
Fernández, M. J. N., Reglero, C. M., Rodríguez, J. A. N., Piñeiro, A. C., Sixto, L. B., Peiró, A. M., Santos, J. T., Visonà, A., Fernández-Reyes, J. L., Bosch, M. M., Adarraga, M., Agud, M., Aibar, J., Aibar, M., Amado, C., Arcelus, J., Baeza, C., Ballaz, A., Barba, R., …, & Encabo, M. (2020). First three months of anticoagulation for venous thromboembolism in non-cancer patients: LMWH VS. VKAs. Findings from the RIETE registry. Thrombosis Update. https://doi.org/10.1016/j.tru.2020.100010
Vancouver
Fernández MJN, Reglero CM, Rodríguez JAN, Piñeiro AC, Sixto LB, Peiró AM, et al. First three months of anticoagulation for venous thromboembolism in non-cancer patients: LMWH VS. VKAs. Findings from the RIETE registry. Thrombosis Update. 2020. doi:10.1016/j.tru.2020.100010
BibTeX
@article{Fernndez2020,
author = {Fernández, Manuel J. Núñez and Reglero, Cristina Martínez and Rodríguez, José Antonio Nieto and Piñeiro, Ana Chouza and Sixto, Laura Barcia and Peiró, Ana Maestre and Santos, Javier Trujillo and Visonà, Adriana and Fernández-Reyes, José Luis and Bosch, Manuel Monreal and Adarraga, M.D. and Agud, M. and Aibar, J. and Aibar, M.A. and Amado, C. and Arcelus, J.I. and Baeza, C. and Ballaz, A. and Barba, R. and Barbagelata, C. and Barrón, M. and Barrón-Andrés, B. and Bernal, M. and Blanco-Molina, A. and Botella, E. and Camon, A.M. and Cañas, I. and Casado, I. and Castro, J. and Chasco, L. and Criado, J. and Ancos, C. de and Miguel, J. de and Toro, J. del and Demelo-Rodríguez, P. and Díaz-Peromingo, J.A. and Campli, M.V. Di and Díez-Sierra, J. and Domínguez, I.M. and Encabo, M.},
title = {First three months of anticoagulation for venous thromboembolism in non-cancer patients: LMWH VS. VKAs. Findings from the RIETE registry},
journal = {Thrombosis Update},
year = {2020},
doi = {10.1016/j.tru.2020.100010}
}
EUVIMED